Ämnen: Forskning

New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis

1 Oktober 2015 08:00

The New England Journal of Medicine (NEJM) has published positive results from two pivotal, multi-centre, Phase III studies – AMAGINE-2 and AMAGINE-3 - demonstrating that treatment with brodalumab resulted in significant clinical improvements in patients with moderate to severe psoriasis and was superior to both placebo and ustekinumab, a leading approved treatment for psoriasis.

​Moventig in i högkostnadsskyddet

28 September 2015 09:51

Tandvårds- och läkeförmånsnämnden har beslutat att AstraZenecas läkemedel Moventig® (naloxegol) nu ingår i läkemedelsförmånen endast för patienter med opioidorsakad förstoppning med otillräckligt behandlingssvar på laxermedel. Det innebär att subvention ges i enlighet med läkemedlets godkända indikation.

AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and lynparza™ (olaparib)

24 September 2015 08:02

AstraZeneca, along with MedImmune, the company’s global biologics research and development arm, will illustrate the strength and depth of research underpinning its scientific leadership in oncology, at the European Cancer Congress (ECC) 2015 in Vienna, Austria (25-29 September 2015).

AstraZeneca to present data demonstrating diversity of its portfolio of innovative formulations and devices at the ERS international congress 2015

22 September 2015 09:03

AstraZeneca will present 33 abstracts from across the respiratory disease portfolio at the 2015 European Respiratory Society (ERS) meeting in Amsterdam, Netherlands, 26-30 September

AstraZeneca presents positive pooled analysis demonstrating the effect of dapagliflozin on albuminuria in hypertensive patients with type 2 diabetes

17 September 2015 16:31

AstraZeneca today announced findings from a new post-hoc analysis of two Phase III trials, in which dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, 5 and 10 mg/d demonstrated greater reductions on HbA1c and systolic blood pressure (SBP) in patients with type 2 diabetes

Ny studie visar överlevnadsfördel för Faslodex (fulvestrant) jämfört med Arimidex (anastrozol) hos kvinnor med avancerad östrogenpositiv bröstcancer

16 September 2015 08:30

AstraZeneca tillkännagav i dag publiceringen av viktiga data om total överlevnad (overall survival OS) från FIRST*-studien, en randomiserad, öppen multicenterstudie i fas II där man jämför första linjens behandling med östrogenreceptorantagonisten Faslodex® (fulvestrant) 500 mg mot aromatashämmaren Arimidex® (anastrozol), hos postmenopausala kvinnor med ER-positiv bröstcancer i avancerat stadium.

ASTRAZENECA TO PRESENT COMPREHENSIVE DATA FROM ITS DIABETES PORTFOLIO AND PRE-CLINICAL RESEARCH

11 September 2015 09:03

11 September 2015
AstraZeneca today announced that 54abstracts from the company’s research and development in diabetes will be presented at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden, 14-18 September 2015.
The presentations will include data on a number of approved products for the treatment of type 2 diabetes, including Forxiga®

ASTRAZENECA PURCHASES US BIOLOGICS MANUFACTURING FACILITY TO SUPPORT GROWING PIPELINE

11 September 2015 08:01

AstraZeneca today added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc. Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines.

Unikt samarbete mellan industri och akademi kring avancerad utrustning ger nya möjligheter att angripa svåra sjukdomar

9 September 2015 13:00

AstraZeneca, Göteborgs universitet och Chalmers meddelar i dag att man ingått ett nytt samarbete kring en avancerad utrustning for masspektrometri som gör att man på ett bättre sätt kan studera hur molekyler interagerar på cellulär nivå.

AstraZeneca to update on leading lung cancer portfolio at WCLC 2015

4 September 2015 09:04

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer (WCLC) 2015, beginning this weekend in Denver, Colorado.

US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack

3 September 2015 22:49

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year..

Positive phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated urinary tract infections

2 September 2015 13:08

​AstraZeneca today announced positive topline results from RECAPTURE 1and RECAPTURE 2, the pivotal Phase III studies evaluating the antibiotic, CAZ-AVI (ceftazidime-avibactam), as a treatment for adult hospitalised patients with complicated Urinary Tract Infections (cUTI), including pyelonephritis.

Ny studie visar på förbättrad följsamhet till behandling efter hjärtinfarkt med hjälp av mobilapp

2 September 2015 09:10

Idag presenterades resultaten från den svenska SUPPORT studien som undersökt effekten på följsamhet och förebyggande insatser efter hjärtinfarkt (sekundärprevention) med hjälp av en mobiltelefonapplikation (”app”).

AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan

2 September 2015 08:02

AstraZeneca today announced that its global biologics research and development arm, MedImmune, has entered an agreement granting Daiichi Sankyo Company, Ltd. (Daiichi Sankyo) an exclusive license to develop and commercialise FluMist® Quadrivalent in Japan.

Ticagrelor (BRILIQUE) i samband med kranskärlskirurgi ger färre blödningskomplikationer jämfört med clopidogrel

1 September 2015 10:00

En ny studie som presenteradesden 1 september under den Europeiska hjärtläkarkongressen i London (ESC) visar att ticagrelor jämfört med clopidogrel minskar risken för allvarliga blödningar i samband med kranskärlskirurgi.

AstraZeneca och Valeant i samarbete om brodalumab

1 September 2015 08:11

AstraZeneca fortsätter att skärpa fokus på sina viktigaste terapiområden och ett samarbete med en expert inom dermatologi förväntas snabba på utvecklingen av brodalumab för patienter med psoriasis och tillgodose ett betydande ouppfyllt behandlingsbehov

Subgruppsanalys från PEGASUS-TIMI 54-studien visar vikten av fortsatt underhållsbehandling med BRILINTA/BRILIQUE i mer än ett år efter en hjärtinfarkt

31 Augusti 2015 16:16

Data som presenterades vid European Society of Cardiologys kongress 2015 betonar behovet av långsiktig sekundärprevention för att förhindra nya hjärt-kärlhändelser

AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015

29 Augusti 2015 09:32

Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations.

AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial

24 Augusti 2015 08:07

AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial wil

AstraZeneca appoints Dr Sean Bohen as Executive Vice President of Global Medicines Development and Chief Medical Officer

24 Augusti 2015 08:06

AstraZeneca today announced the appointment of Sean Bohen MD, PhD, as Executive Vice President of Global Medicines Development and Chief Medical Officer. He will join the company on 15 September.
Dr. Bohen will be responsible for driving the progress of AstraZeneca’s portfolio of small molecules and biologics investigational medicines through late-stage development to regulatory approval. As C